Featured Research

from universities, journals, and other organizations

Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported

Date:
January 9, 2012
Source:
American Association for Cancer Research
Summary:
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to new data.

Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012.

Patients with lung cancer and a KRAS mutation are believed to have a poor prognosis and may not benefit from treatment with epidermal growth factor receptor tyrosine kinase inhibitors, according to study author Wouter W. Mellema, M.D., a doctoral candidate at VU University Medical Center in Amsterdam.

"There is a great need for targeted treatment options for patients with non-small cell lung cancer (NSCLC) with a KRAS mutation," he said.

In the phase 2, multicenter study conducted in the Netherlands, researchers assigned 57 patients with NSCLC and a KRAS mutation to 400 mg of sorafenib twice daily.

At six weeks, Mellema and colleagues reported a rate of no progression of 52.6 percent. Fifteen patients stopped treatment before six weeks -- 10 of whom stopped due to clinical progression. Median progression-free survival was 2.3 months, and median overall survival was 5.3 months. The researchers reported that 14 patients are still alive.

"Sorafenib could be a useful drug in this patient population by inhibiting the growth-stimulating signal of the RAS protein," Mellema said. "However, although sorafenib showed relevant activity, the outcome was unsatisfactory."

Mellema and his team had conducted a pilot study in 10 patients, which showed "very promising results. Unfortunately, the results of the phase 2 study were less optimistic. We expected that progression-free survival and overall survival would be better [in the phase 2 study]," Mellema said.

He suggested that the KRAS mutation causes early progression by stimulating cell growth through an alternative pathway. "Future studies currently in preparation in our group should focus on simultaneous inhibition of these pathways," he said.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported." ScienceDaily. ScienceDaily, 9 January 2012. <www.sciencedaily.com/releases/2012/01/120109211821.htm>.
American Association for Cancer Research. (2012, January 9). Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/01/120109211821.htm
American Association for Cancer Research. "Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported." ScienceDaily. www.sciencedaily.com/releases/2012/01/120109211821.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com
Thousands Who Can't Afford Medical Care Flock to Free US Clinic

Thousands Who Can't Afford Medical Care Flock to Free US Clinic

AFP (July 23, 2014) America may be the world’s richest country, but in terms of healthcare, the World Health Organisation ranks it 37th. Thousands turned out for a free clinic run by "Remote Area Medical" with a visit from the Governor of Virginia. Duration: 2:40 Video provided by AFP
Powered by NewsLook.com
Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins